Physician

Arijit Chakravarty, MD

According to 2025 Medicare claims, Arijit Chakravarty, MD (NPI: 1386778199) practices nephrology in the Memphis, TN-MS-AR market, with the plurality of this provider's patient population coming from De Soto, MS. This provider's primary affiliated billing organization is MID-SOUTH NEPHROLOGY CONSULTANTS PLLC (NPI: 1346219342; TIN: 621650432) and primary practice location at 38671-4739. Chakravarty is affiliated with the ACO West Virginia (ACO ID: A3563), participating under the MSSP model.

Chakravarty's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 378 traditional Medicare patients, billed 1,575 HCPCS/CPT codes, and received $115,392 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 126 prescription claims across 42 beneficiaries totaling $34,735 in drug costs, led by Torsemide (Torsemide). DME data shows 67 claims. Open Payments data shows 11 records totaling $256. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $117,823 to $115,392. In contrast, Part D prescription costs have declined steadily, from $132,837 to $34,735. For DME billing, this smaller-volume category changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	178	1,070	$117,823
2016	148	582	$62,812
2017	215	518	$45,609
2018	258	660	$48,695
2019	N/R	N/R	N/R
2020	209	843	$77,952
2021	496	2,464	$222,370
2022	565	3,646	$276,329
2023	498	3,866	$289,690
2024	378	1,575	$115,392

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	93	1,013	$132,837
2016	86	1,095	$128,985
2017	88	969	$164,205
2018	88	552	$111,877
2019	39	158	$33,098
2020	16	46	$7,456
2021	22	47	$6,900
2022	39	133	$16,591
2023	71	286	$66,414
2024	42	126	$34,735

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	306	2,174	$235,159
2016	301	2,748	$268,430
2017	371	2,807	$254,793
2018	265	912	$79,098
2019	148	544	$34,528
2020	53	212	$5,930
2021	N/R	N/R	N/R
2022	N/R	34	$1,071
2023	N/R	61	$1,241
2024	N/R	67	$1,155

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	142	155	$127
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	180	503	$83
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	134	327	$58
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	48	50	$54
90935	Hemodialysis procedure with physician evaluation	53	100	$52

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Torsemide	Torsemide	12	1,050	$184
Olmesartan Medoxomil	Olmesartan Medoxomil	13	690	$80
Amlodipine Besylate	Amlodipine Besylate	11	750	$50

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	18	$423
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	15	$263
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	17	$239
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	17	$230

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	11	$256	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Arijit Chakravarty, MD?

Tedicare shows public-source Medicare data for Arijit Chakravarty, MD (NPI 1386778199), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Arijit Chakravarty, MD have ACO affiliation data?

Arijit Chakravarty, MD is shown with ACO affiliation data for ACO West Virginia (MSSP, ACO ID A3563).

What billing organization is linked to Arijit Chakravarty, MD?

Arijit Chakravarty, MD is linked to MID-SOUTH NEPHROLOGY CONSULTANTS PLLC (billing NPI 1346219342) in the available physician profile data.

Does Arijit Chakravarty, MD have Open Payments data?

Arijit Chakravarty, MD has 11 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.